



**SUBSCRIBE**

## IPO Report

10<sup>th</sup> Dec'25

### Snapshot

Company is the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds, and the largest private hospital chain in terms of bed capacity in Haryana with 1,600 beds located in the state as of March 31, 2025. Company operate a network of 14 NABH accredited multi-super specialty hospitals under the 'Park' brand, of which eight hospitals are also NABL accredited, with eight hospitals in Haryana, one hospital in New Delhi, three hospitals in Punjab and two hospitals in Rajasthan.

### VALUATION

Company is bringing the issue at price band of Rs 154-162 per share at p/e multiple of 25x on post issue annualized H1FY26 PAT basis.

Company is second largest chain of private hospitals in North India and largest private hospital chain in Haryana with delivering high-quality and affordable healthcare with a diverse specialty mix. Company has track record of successfully acquiring and integrating hospitals along with strong operational and financial performance with diversified payor mix and doctor led professional management team with industry experience. Hence, we recommend "Subscribe" to the issue.

<b>Price Band (Rs./Share)</b>	154-162
<b>Opening date of the issue</b>	10 <sup>th</sup> Dec '2025
<b>Closing Date of the issue</b>	12 <sup>th</sup> Dec '2025
<b>No of shares pre issue</b>	38,43,99,990 Eq Shares
<b>Issue Size</b>	Rs 920.00 Cr
<b>Fresh issue</b>	Rs 770.00 Cr
<b>Offer For Sale</b>	Rs 150.00 Cr
<b>Face Value (Rs/ share)</b>	Rs 2/share
<b>Bid Lot</b>	76
<b>BIDDING DETAILS</b>	
<b>QIBs (Including Anchor)</b>	50% of the offer (Approx 2,83,95,062 eq Shares)
<b>Non-Institutional</b>	15% of the offer (Approx 85,18,519 eq Shares)
<b>Retail</b>	35% of the offer (Approx 1,98,76,543 eq Shares)
<b>Lead managers</b>	Nuvama Wealth Management Limited, CLSA India Private Ltd, DAM Capital Advisors Limited, Intensive Fiscal Services Limited
<b>Registrar to the issue</b>	Kfin Technologies Limited

### WHAT WE LIKE

#### **Second largest chain of private hospitals in North India and largest private hospital chain in Haryana**

Company is the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds, and the largest private hospital chain in terms of bed capacity in Haryana with 1,600 beds located in the state as of March 31, 2025. Company have been providing healthcare services since the incorporation of Company in 2011 and its extensive presence in the North India region has allowed company to develop an understanding of regional nuances, patient culture and preferences, and infrastructure requirements. Over the years, company have increased its bed capacity organically and through the acquisition of other hospitals growing from 2,550 beds as of March 31, 2023 to 3,250 beds as of September 30, 2025.

#### **Track record of successfully acquiring and integrating hospitals**

Company have established a track record of successfully acquiring and integrating hospitals so as to expand its network, which has significantly contributed to the growth in company's bed capacity, revenues and profitability. Company have completed the acquisition of eight hospitals in North India and added 1,650 beds to its network through such initiatives as of September 30, 2025. These acquisitions have helped company expand its geographic reach in key regions of North India and strengthened company's presence enabling it to provide services to more patients.

#### **Strong operational and financial performance with diversified payor mix**

During the six months ended September 30, 2025 and September 30, 2024, and Fiscals 2025, 2024, and 2023, company's in-patient volume was 46,551, 40,368, 81,311; 73,284 and 73,084 patients across its hospitals, respectively, and company's ARPOB was ₹ 27,105, ₹ 25,674, ₹ 26,206; ₹ 24,919 and ₹ 24,575, respectively. Company's restated profit after tax for the six months ended September 30, 2025 and September 30, 2024, and Fiscals 2025, 2024 and 2023 was ₹ 1,391.43 million, ₹ 1,128.90 million, ₹ 2,132.15 million, ₹ 1,520.07 million and ₹ 2,281.86 million, respectively, reflecting company's ability to remain profitable



## COMPANY BACKGROUND

Company offer over 30 super specialty and specialty services, including internal medicine, neurology, urology, gastroenterology, general surgery, orthopedics and oncology. As of September 30, 2025, company had a dedicated team of 1,014 doctors and 2,142 nurses across its hospitals, delivering clinical and patient care.

Company have increased its bed capacity from 2,550 beds as of March 31, 2023 to 3,250 beds as of September 30, 2025; and company currently have a pipeline of hospital expansion in Ambala, Panchkula, Rohtak, New Delhi, Gorakhpur and Kanpur. In Ambala, company have bought land adjacent to its existing hospital and are in the process of increasing its bed capacity from 250 beds to 450 beds and set up an onco-radiation facility, which is expected to be operational by October 2027. In Panchkula, company is in the process of constructing a multi super-specialty hospital with a capacity of 300 beds, which is expected to be operational by April 2026, while in Rohtak, company is constructing a hospital with a capacity of 250 beds, which is expected to be operational by December 2026. In addition, Blue Heavens, a Subsidiary of Company, submitted a Resolution Plan to the resolution professional appointed in respect of Durha Vittrak under the provisions of the Insolvency and Bankruptcy Code, 2016, for the proposed acquisition of Durha Vittrak (operating as Febris Multi Specialty Hospital, Narela, New Delhi). Pursuant to the NCLT Order, the Resolution Plan was approved. Blue Heavens is in the process of completing the requisite steps as specified in the NCLT Order and the Resolution Plan, including:

- i payment of ₹ 483.01 million to the secured financial creditors of Durha Vittrak; and
- i infusion of ₹1.00 million by Blue Heavens in the form of equity capital towards subscription of fresh equity shares of Durha Vittrak.

Upon completion of the aforesaid steps, including the subscription to the share capital of Durha Vittrak, as specified in the Resolution Plan and the NCLT Order, Durha Vittrak will become a wholly-owned subsidiary of Blue Heavens.

As of September 30, 2025, company's hospitals were equipped with an aggregate of 870 bedded intensive care units ("ICUs") and 67 operating theatres ("OTs"), as well as a dedicated oxygen generation plant for critical care at each hospital. Company also have two dedicated cancer units that are equipped with linear accelerators. Each of company's hospitals have a trauma center with round-the-clock coverage from super specialists, anesthesiologists and intensivists for its patients. Company have established Institutes of Minimal Access, Advanced Surgical Sciences and Robot-Assisted Surgery ("iMARS") at three of its hospitals in Sector 47, Gurugram; Palam Vihar; and Mohali to deliver advanced clinical care by leveraging robotic systems to provide a comprehensive range of minimally invasive procedures that lead to quicker recovery and improved outcomes for its patients.

Company is led by its founder and Chairman, Dr. Ajit Gupta, whose leadership and deep understanding of the healthcare landscape in India has laid the foundation for company's growth. Dr. Ajit Gupta has over 25 years of experience in the medical profession. Company's Managing Director, Dr. Ankit Gupta, has over 20 years of experience in the medical profession and has been instrumental in transforming company's chain of hospitals into a trusted brand in North India.

## OBJECTS OF OFFER

The Offer comprises of the Fresh Issue of Equity Shares of face value of ₹2 each, aggregating up to ₹ 7,700.00 million by Company and an Offer for Sale of Equity Shares of face value of ₹2 each, aggregating up to ₹ 1,500.00 million by the Promoter Selling Shareholder.

### Fresh Offer

Company proposes to utilize the Net Proceeds towards funding the following objects

1. Repayment/ prepayment, in full or in part, of outstanding borrowings availed by Company and its Subsidiaries;
2. Funding capital expenditure for development of new hospital by company's Subsidiary, Park Medicity (NCR);
3. Funding capital expenditure for purchase of medical equipment by Company and its Subsidiaries, Blue Heavens and Ratangiri; and
4. Unidentified inorganic acquisitions and general corporate purposes.

## RISKS

Company have certain contingent liabilities that have been disclosed in its financial statements. As of September 30, 2025, company's contingent liabilities (excluding corporate guarantees) constituted 11.66% of its net worth, while corporate guarantees given by Company and Subsidiaries constituted 71.58% of company's net worth. If these liabilities materialize, they may adversely affect company's results of operations, cash flows and financial condition.

Source:RHP



**Consolidated Financials**

**(Rs in Mn)**

<b>Financials</b>	<b>FY23</b>	<b>FY24</b>	<b>FY25</b>	<b>H1FY26</b>
Total Revenue (A)	12545.95	12310.66	13935.70	8086.57
Total Expenditure (B)	8642.54	9207.65	10213.97	5915.21
EBIDTA	3903.41	3103.01	3721.73	2171.36
EBIDTA Margin	31.11	25.21	26.71	26.85
Other Income	175.82	320.18	324.04	147.37
Depreciation	405.16	505.74	582.25	283.15
EBIT	3674.07	2917.45	3463.52	2035.58
Interest	506.02	703.18	596.77	296.63
PBT	3168.05	2214.27	2866.75	1738.95
Share of profit in Asso	0.00	0.00	0.00	0.00
PBIT	3168.05	2214.27	2866.75	1738.95
Exceptional	17.77	32.64	0.00	0.00
PBT	3150.28	2181.63	2866.75	1738.95
Tax	868.42	661.56	734.60	347.52
PAT	2281.86	1520.07	2132.15	1391.43
NPM	18.19	12.35	15.30	17.21
ROE%	32.91	18.81	20.08	11.45
EPS	5.94	3.95	5.55	3.62
Eq Cap	768.80	768.80	768.80	768.80
Net Worth	7,299.72	9,355.06	11,262.77	12,646.75

(Source: RHP)



## **DISCLAIMER**

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services, merchant banking services, Portfolio Management Services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to this statement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.